INTRODUCTION
The aqueous solubility of a drug is a key determinant of its oral bioavailability. There are some drugs for which solubility has presented a challenge to the development of a suitable formulation for oral administration. Drug absorption, sufficient and reproducible bioavailability, pharmacokinetic profile of orally administered drug substances is highly dependent on aqueous solubility of that compound (Jatwani et al., 2012; Wagh and Wagh, 2015) . More than 40% of new drugs have poor aqueous solubility, resulting in unsatisfactory oral drug delivery. Thus, increased solubility, dissolution rate and bioavailability of drug have a very crucial role in the process of drug development (Yogesh et al., 2011) . Besides this, BCS II drugs are very much prone to dissolution-rate limited gastrointestinal absorption (Shohin et al., 2011; Reddy et al., 2011) . Hence, by improving drug dissolution in aqueous medium, various formulation techniques can accelerate a parallel improvement in bioavailability (Wei and Lobenber, 2006; Kawabata et al., 2011; Kawakami, 2012) .
Drug dissolution enhancement has been extensively studied over the past decade through different techniques (Ahuja et al., 2007; Blagden et al., 2007; Cilurzo et al., 2008; Makar et al., 2013) . Among these, the SD technique is the most successful in improving the dissolution and bioavailability of poorly soluble active pharmaceutical ingredients because it is very simple and economic (Leuner and Dressman, 2000; Chiou and Rigelman, 1971; Serajuddin, 1999) . Solid lipid nanoparticles (SLN) are aqueous colloidal dispersions, is made up of solid biodegradable lipids having a lot of the advantages with a limited drawbacks (Swathi et al., 2010; Sarathchandiran, 2012) .
ethyl, is an antidiabetic drug originated from the second generation sulphonyl urea group and stimulates the release of insulin. It is also classified as class II drug according to biopharmaceutical classification system and used for treatment of non-insulin-dependent diabetes mellitus (Frick et al., 1998; Massimo, 2003) . In acidic and neutral aqueous media, glimepiride shows very poor solubility at 37°C (<0.004 mg/ml). Solubility of drug is slightly increased by 0.02 mg/ml in media having pH>7. Poor dissolution and unsatisfied bioavailability of this drug are the results of this poor aqueous solubility (Frick et al., 1998) . Previous reports on this drug revealed that dissolution rate is increased through formation of inclusion complex with cyclodextrin (Ammar et al., 2006) or preparation of solid dispersions using either water soluble carriers (Boregowda et al., 2011; Rajpurohit et al., 2011) , insoluble carriers (Kiran et al., 2009; Reven et al., 2010; Vidyadhara et al., 2011) or preparation of spray congealed microparticles (Ilić et al., 2009) . However, for improving its bioavailability only a few attempts have been made. Hence, the present investigation was done to improve the dissolution rate as well as bioavaibility of glimepiride by the preparation of solid lipid nano particle dispersion using glyceryl monostearate and stearic acid as solid lipid and by formation of inclusion complex with β-cyclodextrin and urea crystal.
MATERIALS AND METHODS

Materials
Glimepiride was a gift sample from Beximco Pharmaceuticals, Dhaka, Bangladesh. Glyceryl monostearate and stearic acid were procured from Balami Fine Chemicals, India. Tween 80 and lutrol F-68 (poloxamer) were received from Merk chemicals, Mumbai, India. Betacy-
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clodextrin, urea crystals were obtained from BASF, Germany. All other reagents and solvent used were of analytical grade.
Preparation of solid lipid nanoparticle dispersions by hot homogenization method
Solid lipid nanoparticle dispersions were prepared by hot homogenization technique (Mehnert and Mader, 2001) . Lipid was melted at temperature ten degrees above its melting point then glimepiride was added to the melted lipid. The dispersion was kept at the same temperature until it is appeared as optically clear. Tween 80 as stabilizer was dissolved in distilled water and heated at the same temperature of lipid mixture. Hot surfactant solution was then added to the melted lipid-drug mixture and emulsified by a homogenizer at 12000 rpm for 2 hours. The formulation was then removed from water bath and the dispersion of SLN was mixed gently at room temperature (table 1) .
Preparation of solid dispersions by precipitation method
For the preparation of solid dispersion glimepiride (GMP) was dissolved in ethanol and β -cyclodextrin (β -CD) was dissolved in distilled water at room temperature (Sapkal et al., 2007) . Different ratios of drug, β-CD and urea crystal were taken (table 2). The mixture was stirred at room temperature for one hour and then slowly evaporated on a boiling water bath. The precipitates as a crystalline powder was pulverized followed by screening through sieve No. 100 and stored in a desiccator till free from any traces of the organic solvent.
In vitro dissolution studies
In vitro dissolution studies of the pure drug, solid dispersions and market preparations were carried out to estimate the cumulative percentage of drug release with respect to time (Khan and Rhodes, 1975) . Distilled water (900ml) was placed in each vessel of the USP type II rotating paddle dissolution apparatus (Veego Vda 6DR, Germany). Two capsules or SDs granules (equivalent to 2mg of drug) were placed in each vessel and the medium was allowed to equilibrate at 50 rpm to a temperature of 37±0.5°C for 45 minutes. 10ml of the sample was withdrawn at definite time interval (5, 10, 20, 30 , and 45 minutes) consecutively and replaced by fresh media to maintain the sink condition. The absorbances of sample were measured at λmax 236nm on a UV-Visible spectrophotometer (UVmini-1240, Shimadzu, Kyoto, Japan).
Release kinetic modeling
The release pattern of drug from the dosage forms has been described by a number of kinetic models. As we know that the drug release, in vivo performance may be altered by qualitative and quantitative changes in a formulation thus in vitro drug dissolution data can be used in the rational development of controlled release formulations (Dash et al., 2010) .
Zero-order model
In zero order kinetics the drug release rate is independent of the initial concentration (Hadjiioannou et al., 1993) i.e., whatever the amount of drug at absorption site release rate remains the same.
Ct = C0 + K0t
Where, Ct is the amount of drug dissolved in time t, C0 is the initial amount of drug in the solution (most times, C0 = 0), K0 is the zero-order release rate constant expressed in concentration / time and t is the time in hours. The data obtained from in vitro drug release studies were plotted as cumulative amount of drug released versus time.
First-order model
The rate of appearance of drug at the absorption site can be measured by an exponential process (Bourne, 2002) in which the rate of release is only dependent on the remaining drug concentration.
2.303
kt C Log C Log 0   Where, C is the concentration of drug at time t, C0 is the initial concentration, K is the first order release rate constant expressed in time-1 . The data are plotted as log cumulative percentage of drug remaining versus time which would obtain a straight line with a slope of -K/2.303
Korsmeyer-Peppas Model
To describe the drug release phenomenon from polymeric systems, the Korsmeyer-Peppas equation (Korsmeyer et al., 1983 ) is used usually.
Where Mt is the amount of drug release at time t; Mf is the amount of drug release after infinite time; k is a release rate constant; n is the diffusional exponent indicating the mechanism of drug release. The log of percentage drug dissolved is plotted against log time for each formulation. A value of n = 0.45 indicates Fickian diffusion (case-I) release; 0.45 < n < 0.89 for non-Fickian diffusion (anomalous) release; n = 0.89 case-II transport and n > 0.89 indicates super case II release.
Mean Dissolution Time (MDT)
Mean Dissolution Time (MDT) value is a model independed approach and can be calculated from dissolution data using Mockel and Lippold equation (Mockel and Lippold, 1993) . This value can be used to characterize the drug release rate from the dosage form and the retarding efficiency of the polymer. 
Successive fractional dissolution time
To characterize the drug release rate in different experimental condition, T25% (time required for 25% drug release), T50%, T80% and MDT were calculated from dissolution data according to the equations: T25% = (0.25/k) 1/n , T50% = (0.5/k) 1/n , T80% = (0.8/k) 1/n and MDT = (n/n+1) k -1/n where n is a release exponent and k is the release rate constant for Korsmeyer-Peppas equation. 
Statistical analysis
RESULTS
Different combination of lipid and polymer were used to provide glimepiride solid lipid nano particle dispersions.
The dissolution profile of all the formulations were fitted to zero order, first order and Korsmeyer-Peppas model to ascertain the kinetic modeling of drug release (figure 1, 2 and 3, respectively). Table 3 showed data analysis of release profiles according to different kinetic models. It was found that the in vitro drug release was best explained by Korsmeyer-Peppas equation as the plots showed good linearity (r 2 = 0.901) followed by zero order (r 2 = 0.972) and first order (r 2 = 0.909). The values of n (release exponent) for all formulations studied here were between 0.741 to 0.986 indicating an anomalous behavior corresponding to diffusion, erosion and swelling mechanisms of drug release. Solid dispersions formulated with different carriers exhibited significant improvement in the dissolution (table 4) of glimepiride as compared to pure drug. GMLN3 and GMP2 showed highest dissolution rate that is 111.82% and 109.09% respectively whereas the release percentage of pure drug was 34.09%. Successful fractional dissolution time and MDT values calculated for all the SLNPs were illustrated in figure 4. This finding was also corroborated with the drug release process indicating that GMLN3 and GMP2 had least MDT values 19.572 min and 25.692 min respectively compared to other formulations. In order to evaluate the drug dissolution profile with optimized formulation and market preparation of glimepiride as well as pure drug, it was interesting to compare the results of the dissolution tests ( figure 5 ).
The results revealed that optimized formulation (GMLN3, GMP2) showed highest drug release rate than market preparation.
DISCUSSION
The kinetic modeling of drug release shows that these models have been established to describe the relationship between drug dissolution and drug release patterns mathematically. The corresponding plot (log cumulative percent drug release versus time) for the Korsmeyer Peppas equations indicated a good linearity (r 2 = 0.901). Value of the release exponent 'n' was in between 0.741 and 0.986, indicating anomalous diffusion, i.e., drug release was controlled by more than one process. Reddy et al (2003) observed similar results with a matrix tablet of nicorandil with an n value of 0.71. From the proposed formulation, it is evident that when excipient glyceryl monostearate is used in hot homogenization method, the drug release increases significantly from solid lipid nano particles due to wetting ability and converting crystalline to amorphous form which enhance the solubility. This lipid also increases the entrapment efficiency of glimepiride by increasing the viscosity of medium which prevents rapid diffusion of glimepiride into bulk of medium (Yang, 2000) . When this polymer is used the release percentage has been increased from 34.09% (pure drug) to 111.82%. This results are clear indication that glyceryl monostearate has lower drug retarding ability which is confirmed by smaller MDT value (19.572 min). Lutrol F-68 and glyceryl monostearate or stearic acid can act as gelling agent at high concentration and it affect the drug dissolution from solid lipid nano particles. When stearic acid is used instead of glyceryl monostearate drug release was almost near (90.00%) to that of glyceryl monostearate.
In case of precipitation method, when β-cyclodextrin and glimepiride is formulated as 1:1 ratio, the drug release rate is 81.82%, but in case of 1:3 ratio, the release rate is increased to 109.09%. On the other hand, when urea crystal is used instead of β-cyclodextrin, then the drug release rate is 50.45% which is not as high as betacyclodextrin containing formulation. So, it is clear that the polymer β-cyclodextrin in higher amount used in precipitation method can give very much better dissolution rate. It was verified that the presence of β-cyclodextrin into polymeric drug delivery systems can also influence the drug release mechanism by Bibby et al (Bibby et al., 2000) . In the present study, the results evidenced that release profiles of these formulations were only slightly slower than those containing glyceryl monosterate. This is probably due to an inclusion process of the glimepiride molecule in β-cyclodextrin, which may be considered energetically favoured when compared to inclusion of drugs, namely ibuprofen (Bragga et al., 2003) . So, the present study confirms that solid lipid nanoparticles of glimepiride with lipid, surfactant and stabilizer and precipitated formulation from large amount of β-cyclodextrin can be formulated as tablet with better dissolution characteristics.
CONCLUSION
The results of the present study provide useful information on the type of lipid and polymer that should be employed on the formulation of glimepiride solid lipid nano particle dispersion. The release mechanism of glimepiride from each formulation tested was evaluated in the light of zero order, first order and KorsmeyerPeppas kinetic models. The Korsmeyer-Peppas model fits with the in vitro dissolution data and gives an insight into the possible drug release mechanism by Non-Fickian diffusion. In-vitro drug release through the USP type-Π apparatus from the prepared SLNPs containing glyceryl monostearate is much higher (111.82%) than the pure drug (34.09%) by hot homogenization method. Again in case of precipitation method the formulation containing β-cyclodextrin provide higher drug release (109.09%). Hence glimepiride SLNPs formulated with glyceryl monostearate and β-cyclodextrin enhance the dissolution rate as well as it will enhance the bioavailability of the drug and will increase the patient compliance.
